Symptom Response in NSCLC Patients Treated with Erlotinib: QOL Analysis of the NCIC CTG BR.21 Trial

Reviewer: S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 17 de mayo del 2005

Translation for this article does not exist


Catherine and Finn
by OncoLink Editorial Team
December 01, 2015